Lamivudine powder and preparation method thereof

A technology of lamivudine and powder, applied in antiviral agents, digestive system, powder delivery, etc., can solve the problem that lamivudine tablets are not suitable for children, the elderly and patients with dysphagia, etc. Fast-acting, easy-to-absorb, fast-dissolution effects

Inactive Publication Date: 2011-01-26
天津市医药集团技术发展有限公司
View PDF4 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0009] The present invention aims to overcome the problems that the lamivudine tablets on the market are not suitable for children, the elderly and patients with dysphagia to take, and has prepared an oral powder that is not only suitable for adults but also suitable for children, the elderly and patients with dysphagia. Improved patient compliance with medication

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Lamivudine powder and preparation method thereof
  • Lamivudine powder and preparation method thereof
  • Lamivudine powder and preparation method thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0039] Raw materials: lamivudine raw material 20g.

[0040] The preparation method of lamivudine powder comprises the following processing steps:

[0041] (1) Take the raw material and dry it until the moisture is 0.4%;

[0042] (2) the raw material after drying is crossed 80 mesh sieves;

[0043] (3) Take medicinal strip-shaped composite packaging film (SP film) as packaging material, fill on SP packaging machine, prepare 1000 bags,

[0044] Each bag contains lamivudine 20mg.

Embodiment 2

[0046] Raw material: 50g of lamivudine raw material.

[0047] The preparation method of lamivudine powder comprises the following processing steps:

[0048] (1) Take the raw material and dry it until the moisture is 0.4%;

[0049] (2) the raw material after drying is crossed 80 mesh sieves;

[0050] (3) Use paper-aluminum composite film as packaging material, fill on a single-row horizontal packaging machine, and prepare 1000 bags, each bag containing 50 mg of lamivudine.

Embodiment 3

[0052] Raw materials: lamivudine raw material 100g.

[0053] The preparation method of lamivudine powder comprises the following processing steps:

[0054](1) Take the raw material and dry it until the moisture is 0.2%;

[0055] (2) the raw material after drying is crossed 80 mesh sieves;

[0056] (3) Take the medicinal strip-shaped composite packaging film (SP film) as the packaging material, fill it on the SP packaging machine, and prepare 1000 bags, each containing 100 mg of lamivudine.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
particle size (mesh)aaaaaaaaaa
Login to view more

Abstract

The invention discloses lamivudine oral powder. The powder is prepared by sealing 20-300mg of lamivudine without any auxiliary materials with a proper pharmaceutical packaging material, such as a paper aluminum composite film or a strip composite packaging film (SP film for short), wherein the moisture content of lamivudine is controlled to be 0.1 to 0.5 percent, and the grain size is 80-100 meshes. The lamivudine powder is fast in vitro dissolution rate, strong in stability and reasonable in clinical application, saves the auxiliary materials and the process cost, has simple productive process, is relatively easier to meet the medicament standard, and is more suitable for large-scale industrialized production. Therefore, the invention provides a new kind of preparation for the clinical use of the lamivudine medicament.

Description

technical field [0001] The invention belongs to the technical field of pharmaceutical preparations, and relates to antiviral drug lamivudine powder and a preparation method thereof. Background technique [0002] Lamivudine is an essential product among nucleoside analogue antiviral drugs, and it is the first-line treatment drug for hepatitis B virus and HIV infection. [0003] Lamivudine has a strong inhibitory effect on hepatitis B virus (HBV) in vitro and in experimentally infected animals. Lamivudine can be metabolized in HBV-infected cells and normal cells to produce lamivudine triphosphate, which is the active form of lamivudine, which is both an inhibitor of HBV polymerase and a substrate of this polymerase. Lamivudine triphosphate does not interfere with the metabolism of deoxynucleosides in normal cells, and has almost no effect on the DNA content of mammalian cells. Lamivudine has no obvious toxicity to the structure, DNA content and function of mitochondria. The ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K9/14A61K31/513A61P1/16A61P31/18A61P31/20A61P31/12
Inventor 苏艳华宫雪孟红赵平
Owner 天津市医药集团技术发展有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap